Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Diwakar Davar(University of Pittsburgh Medical Center), Robert M. Morrison(UPMC Hillman Cancer Center), Amiran Dzutsev(National Cancer Institute), Arivarasan Karunamurthy(UPMC Hillman Cancer Center), Joë-Marc Chauvin(University of Pittsburgh), F. Amatore(UPMC Hillman Cancer Center), Julie S. Deutsch(Johns Hopkins University), Rodrigo X. Das Neves(UPMC Hillman Cancer Center), Richard R. Rodrigues(Frederick National Laboratory for Cancer Research), John A. McCulloch(National Cancer Institute), Hong Wang(University of Pittsburgh), Douglas J. Hartman(UPMC Hillman Cancer Center), Jonathan H. Badger(National Cancer Institute), Miriam R. Fernandes(National Cancer Institute), Yulong Bai(University of Pittsburgh), Jie Sun(University of Pittsburgh), Alicia M. Cole(National Cancer Institute), Poonam Aggarwal(National Cancer Institute), Jennifer R. Fang(National Cancer Institute), Christopher Deitrick(University of Pittsburgh), Riyue Bao(UPMC Hillman Cancer Center), Umamaheswar Duvvuri(UPMC Hillman Cancer Center), Shaum Sridharan(UPMC Hillman Cancer Center), Seungwon Kim(UPMC Hillman Cancer Center), Haroon A. Choudry(UPMC Hillman Cancer Center), Matthew P. Holtzman(UPMC Hillman Cancer Center), James F. Pingpank(UPMC Hillman Cancer Center), James Patrick O'Toole(UPMC Hillman Cancer Center), Richelle DeBlasio(University of Pittsburgh), Yang Jin(University of Pittsburgh), Quanquan Ding(University of Pittsburgh), Wentao Gao(University of Pittsburgh), Christopher Groetsch(University of Pittsburgh), Ornella Pagliano(University of Pittsburgh), Amy Rose(University of Pittsburgh), Corey Urban(University of Pittsburgh), Jagjit Singh(UPMC Hillman Cancer Center), Prajan Divarkar(Nanostring Technologies (United States)), David Mauro, Dmitri Bobilev, James E. Wooldridge, Arthur Μ. Krieg, Matthew G. Fury(Regeneron (United States)), Jeffrey R. Whiteaker(Fred Hutch Cancer Center), Lei Zhao(Fred Hutch Cancer Center), Amanda G. Paulovich(Fred Hutch Cancer Center), Yana G. Najjar(UPMC Hillman Cancer Center), Jason J. Luke(UPMC Hillman Cancer Center), John M. Kirkwood(UPMC Hillman Cancer Center), Janis M. Taube(Johns Hopkins University), Hyun Jung Park(University of Pittsburgh), Giorgio Trinchieri(National Cancer Institute), Hassane M. Zarour(University of Pittsburgh Medical Center)
Cited by 51Open Access
Abstract
T cells peripherally. MPRs had an enriched pre-treatment gene signature of myeloid cells, and response to therapy was associated with gene signatures of immune cells, pDCs, phagocytosis, and macrophage activation. MPRs gut microbiota were enriched for Gram-negative bacteria belonging to the Bacteroidaceae and Enterobacteriaceae families and the small subgroup of Gram-negative Firmicutes. Our findings support that combined vidutolimod and nivolumab stimulates a broad anti-tumor immune response and is associated with distinct baseline myeloid gene signature and gut microbiota. ClinicalTrials.gov identifier: NCT03618641.
Related Papers
No related papers found
Powered by citation graph analysis